Literature DB >> 29468648

Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.

Yishai Ofran1, Eric Beohou2,3,4,5, Myriam Labopin2,3,4,5, Didier Blaise6, Jan J Cornelissen7, Marco R de Groot8, Gerard Socié9,10, Anne Huynh11, Johan Maertens12, Frederic Baron13, Mohamad Mohty2,3,4,5, Arnon Nagler2,14.   

Abstract

Entities:  

Keywords:  GVHD-free relapse-free survival; acute myeloid leukaemia; anti-thymocyte globulins; chronic graft-versus-host disease; reduced-intensity conditioning

Year:  2018        PMID： 29468648     DOI： 10.1111/bjh.15131

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.

Authors:  Maria H Gilleece; Avichai Shimoni; Myriam Labopin; Stephen Robinson; Dietrich Beelen; Gerard Socié; Ali Unal; Arnold Ganser; Antonin Vitek; Henrik Sengeloev; Ibrahim Yakoub-Agha; Eleni Tholouli; Emmanuelle Polge; Mohamad Mohty; Arnon Nagler
Journal:  Blood Cancer J       Date:  2021-05-12       Impact factor: 11.037

2.  Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

Authors:  Eolia Brissot; Myriam Labopin; Ian Moiseev; J J Cornelissen; Ellen Meijer; Gwendolyn Van Gorkom; Montserrat Rovira; Fabio Ciceri; Laimonas Griskevicius; Didier Blaise; Edouard Forcade; Martin Mistrik; Stephan Mielke; Claude Eric Bulabois; Riitta Niittyvuopio; Eric Deconinck; Annalisa Ruggeri; Jaime Sanz; Alexandros Spyridonidis; Bipin Savani; Sebastian Giebel; Arnon Nagler; Mohamad Mohty
Journal:  J Hematol Oncol       Date:  2020-07-03       Impact factor: 17.388

3.  Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Francesco Saraceni; Myriam Labopin; Arne Brecht; Nicolaus Kröger; Matthias Eder; Johanna Tischer; Hélène Labussière-Wallet; Hermann Einsele; Dietrich Beelen; Donald Bunjes; Dietger Niederwieser; Tilmann Bochtler; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2019-04-25       Impact factor: 17.388

Review 4.  Developing role of B cells in the pathogenesis and treatment of chronic GVHD.

Authors:  Xiaoping Li; Qiangguo Gao; Yimei Feng; Xi Zhang
Journal:  Br J Haematol       Date:  2018-12-26       Impact factor: 6.998

Review 5.  Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant.

Authors:  Abdul Hamid Bazarbachi; Rama Al Hamed; Florent Malard; Mohamad Mohty; Ali Bazarbachi
Journal:  Ther Adv Hematol       Date:  2019-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.